文献速递肝病

非酒精性脂肪性肝病与肌少症独立关联心血管风险

Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

基于2008-2011年韩国国民健康与营养调查数据库(n=7,191),研究分析NAFLD和肌少症对ASCVD风险的影响。结果显示NAFLD和肌少症均与ASCVD高风险概率独立相关,两者共存时风险更高(OR=1.83,P=0.014);在NAFLD患者中,FIB-4定义的显著肝纤维化合并肌少症可叠加增加ASCVD高风险(OR=3.56,P<0.001)。

要点

  • NAFLD与肌少症均独立增加ASCVD高风险概率
  • NAFLD合并肌少症者ASCVD高风险OR为1.83
  • NAFLD伴显著肝纤维化及肌少症者OR达3.56

核心结论

  • NAFLD和肌少症与一般人群ASCVD风险增加显著相关
  • NAFLD合并显著肝纤维化及肌少症可叠加增加ASCVD高风险

研究设计与样本

  • 分析2008-2011年韩国国民健康与营养调查数据库,样本量n=7,191
  • 肌少症指数用双能X线吸收法计算,肌少症定义为最低五分位值(男性切点0.882,女性0.582)
  • NAFLD定义为综合NAFLD评分≥40,肝纤维化用FIB-4指数评估
  • ASCVD风险按美国心脏病学会/美国心脏协会指南评估,高风险定义为ASCVD风险>10%

主要发现

  • NAFLD患病率为31.2%(n=2,241),肌少症患病率为19.5%(n=1,400)
  • ASCVD风险评分四分位分层与NAFLD和肌少症均呈正相关(所有趋势P<0.001)
  • 同时患NAFLD和肌少症者较无两者对照,ASCVD高风险概率的OR=1.83(P=0.014)
  • NAFLD患者中,FIB-4定义的显著肝纤维化合并肌少症者较无两者对照,ASCVD高风险概率的OR=3.56(P<0.001)

临床怎么用

  • 对NAFLD患者应评估肌少症和肝纤维化以识别ASCVD高风险人群
  • 肌少症与NAFLD共存时需加强心血管风险评估

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) and sarcopenia have a close association with an increased risk of atherosclerotic cardiovascular disease (ASCVD). This study investigated the influence of NAFLD and sarcopenia on ASCVD risk. METHODS: Data from the 2008-2011 Korean National Health and Nutrition Examination Surveys database were analyzed (n = 7,191). The sarcopenia index was calculated using dual-energy x-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cutoffs = 0.882 for men and 0.582 for women). NAFLD was defined as a comprehensive NAFLD score ≥40. Liver fibrosis was assessed using the fibrosis-4 (FIB-4) index. ASCVD risk was evaluated using American College of Cardiology/American Heart Association guidelines. High probability of ASCVD was defined as ASCVD risk >10%. RESULTS: The prevalence rates of NAFLD and sarcopenia were 31.2% (n = 2,241) and 19.5% (n = 1,400), respectively. The quartile-stratified ASCVD risk scores were positively associated with NAFLD and sarcopenia (all P for trend < 0.001). Subjects with both NAFLD and sarcopenia had a higher risk for high probability of ASCVD (odds ratio = 1.83, P = 0.014) compared with controls without NAFLD and sarcopenia. Among subjects with NAFLD, FIB-4-defined significant liver fibrosis and sarcopenia additively raised the risk for high probability of ASCVD (odds ratio = 3.56, P < 0.001) compared with controls without FIB-4-defined significant liver fibrosis or sarcopenia. DISCUSSION: NAFLD and sarcopenia were significantly associated with an increased risk of ASCVD in the general population. In addition, NAFLD with significant liver fibrosis and sarcopenia were significantly associated with an increased risk of ASCVD in subjects with NAFLD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Han E, Lee YH, Kim YD, et al. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. Am J Gastroenterol. 2020. PMID: 32141917. doi:10.14309/ajg.0000000000000572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。